PDE4: A novel target in the treatment of chronic obstructive pulmonary disease

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 1, 2012, Pages 134-142

  Michalski, J M ^a   Golden, G ^a   Ikari, J ^a   Rennard, S I ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; GSK 256066; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST; ROLIPRAM; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; UK 500 001; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANXIETY; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; INFLUENZA; INSOMNIA; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SUICIDE ATTEMPT; WEIGHT REDUCTION;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DRUG DELIVERY SYSTEMS; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84055207673     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.266     Document Type: Review

References (78)

1. Conti, M. & Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76:481-511 (2007).
2. Jeon, Y.H. et al. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell. Mol. Life Sci. 62, 1198-1220 (2005). (Pubitemid 40880125)
3. Perry, M.J. & Higgs, G.A. Chemotherapeutic potential of phosphodiesterase inhibitors. Curr. Opin. Chem. Biol. 2, 472-481 (1998). (Pubitemid 128645700)
4. Falk, J.A., Philip, K.J. & Schwarz, E.R. The emergence of oral tadalafil as a oncedaily treatment for pulmonary arterial hypertension. Vasc. Health Risk Manag. 6, 273-280 (2010).
5. A damo, C.M. et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. USA 107, 19079-19083 (2010).
6. Wachtel, H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22, 267-272 (1983). (Pubitemid 13144221)
7. Stehlik, J. & Movsesian, M.A. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. Expert Opin. Investig. Drugs 15, 733-742 (2006).
8. De Backer, T., Vander Stichele, R., De Buyzere, M., De Backer, G. & Van Bortel, L. Silence of the limbs pharmacological symptomatic treatment of intermittent claudication. Curr. Vasc. Pharmacol. 8, 383-387 (2010).
9. Banner, K.H. & Press, N.J. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br. J. Pharmacol. 157, 892-906 (2009).
10. Fabbri, L.M., Begh B., Yasothan, U. & Kirkpatrick, P. Roflumilast. Nat. Rev. Drug Discov. 9, 761-762 (2010).
11. Torphy, T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157, 351-370 (1998). (Pubitemid 28090521)
12. Houslay, M.D. & Adams, D.R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370, 1-18 (2003). (Pubitemid 36259414)
13. MacKenzie, S.J. & Houslay, M.D. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-responseelement-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem. J. 347, 571-578 (2000). (Pubitemid 30229406)
14. Houslay, M.D. PDE4 cAMP-specific phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 69, 249-315 (2001). (Pubitemid 33805840)
15. Sette, C. & Conti, M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J. Biol. Chem. 271, 16526-16534 (1996). (Pubitemid 26239006)
16. MacKenzie, S.J., Baillie, G.S., McPhee, I., Bolger, G.B. & Houslay, M.D. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOHterminal docking sites and NH2-terminal UCR regions. J. Biol. Chem. 275, 16609-16617 (2000). (Pubitemid 30398887)
17. Ekholm, D., Belfrage, P., Manganiello, V. & Degerman, E. Protein kinase A-dependent activation of PDE4 (cAMP-specific cyclic nucleotide phosphodiesterase) in cultured bovine vascular smooth muscle cells. Biochim. Biophys. Acta 1356, 64-70 (1997). (Pubitemid 27132803)
18. Sette, C., Iona, S. & Conti, M. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J. Biol. Chem. 269, 9245-9252 (1994). (Pubitemid 24209251)
19. Hoffmann, R., Wilkinson, I.R., McCallum, J.F., Engels, P. & Houslay, M.D. cAMPspecific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem. J. 333 (Pt 1), 139-149 (1998). (Pubitemid 28342503)
20. Baillie, G.S., MacKenzie, S.J., McPhee, I. & Houslay, M.D. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br. J. Pharmacol. 131, 811-819 (2000).
21. Hoffmann, R., Baillie, G.S., MacKenzie, S.J., Yarwood, S.J. & Houslay, M.D. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 18, 893-903 (1999). (Pubitemid 29082269)
22. Hill, E.V., Sheppard, C.L., Cheung, Y.F., Gall, I., Krause, E. & Houslay, M.D. Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to activate cAMP phosphodiesterase-4D3 (PDE4D3) through multi-site phosphorylation at Ser239 and Ser579. Cell. Signal. 18, 2056-2069 (2006). (Pubitemid 44488666)
23. MacKenzie, K.F. et al. Phosphorylation of cAMP-specific PDE4A5 (phosphodiesterase-4A5) by MK2 (MAPKAPK2) attenuates its activation through protein kinase A phosphorylation. Biochem. J. 435, 755-769 (2011).
24. Li, X. et al. Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. Biochem. J. 428, 55-65 (2010).
25. Grange, M. et al. The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site. J. Biol. Chem. 275, 33379-33387 (2000).
26. Noz, G., Sette, C. & Conti, M. Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. Mol. Pharmacol. 51, 242-249 (1997). (Pubitemid 27074145)
27. Houslay, M.D. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem. Sci. 35, 91-100 (2010).
28. Wang, G. et al. Effects of beta-arrestin 2 on cytokine production of CD4+ T lymphocytes of mice with allergic asthma. Indian J. Exp. Biol. 49, 585-593 (2011).
29. Perry, S.J. et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 298, 834-836 (2002). (Pubitemid 35231537)
30. Baillie, G.S. & Houslay, M.D. Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr. Opin. Cell Biol. 17, 129-134 (2005). (Pubitemid 40380935)
31. Baillie, G.S. et al. Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N-and C-domains of beta-arrestin using spotimmobilized peptide arrays. Biochem. J. 404, 71-80 (2007). (Pubitemid 46788086)
32. Task, K.A., Collas, P., Kemmner, W.A., Witczak, O., Conti, M. & Task, K. Phosphodiesterase 4D and protein kinase A type II constitute a signaling unit in the centrosomal area. J. Biol. Chem. 276, 21999-22002 (2001).
33. Dodge, K.L. et al. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J. 20, 1921-1930 (2001). (Pubitemid 32397394)
34. Stefan, E. et al. Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J. Am. Soc. Nephrol. 18, 199-212 (2007). (Pubitemid 46053433)
35. Bird, R.J., Baillie, G.S. & Yarwood, S.J. Interaction with receptor for activated C-kinase 1 (RACK1) sensitizes the phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation by protein kinase C. Biochem. J. 432, 207-216 (2010).
36. Collins, D.M. et al. Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA). Cell. Signal. 20, 2356-2369 (2008).
37. Murdoch, H. et al. Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function. J. Cell. Sci. 124, 2253-2266 (2011).
38. Richter, W. et al. Signaling from beta1-and beta2-adrenergic receptors is defined by differential interactions with PDE4. EMBO J. 27, 384-393 (2008). (Pubitemid 351161657)
39. Vicini, E. & Conti, M. Characterization of an intronic promoter of a cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol. Endocrinol. 11, 839-850 (1997). (Pubitemid 27241777)
40. McCahill, A. et al. In cardiac myocytes, cAMP elevation triggers the down-regulation of transcripts and promoter activity for cyclic AMP phosphodiesterase-4A10 (PDE4A10). Cell. Signal. 20, 2071-2083 (2008).
41. Boswell-Smith, V., Cazzola, M. & Page, C.P. Are phosphodiesterase 4 inhibitors just more theophylline? J. Allergy Clin. Immunol. 117, 1237-1243 (2006). (Pubitemid 43795733)
42. Srivani, P., Usharani, D., Jemmis, E.D. & Sastry, G.N. Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design. Curr. Pharm. Des. 14, 3854-3872 (2008).
43. Hirose, R., Manabe, H., Yanagawa, K., Ohshima, E. & Ichimura, M. Differential effects of PDE4 inhibitors on cortical neurons and T-lymphocytes. J. Pharmacol. Sci. 106, 310-317 (2008). (Pubitemid 351366352)
44. Torphy, T.J. et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm. Pharmacol. Ther. 12, 131-135 (1999). (Pubitemid 29366508)
45. Burgin, A.B. et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat. Biotechnol. 28, 63-70 (2010).
46. Global Initiative for Chronic Obstructive Lung Diseases. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. GOLD Report 2009.
47. Minino, A.M., Xu, J. & Kochanck, K.D. Deaths: Preliminary data for 2008. Natl. Vital. Stat. Rep. 59 (2010).
48. Halbert, R.J., Natoli, J.L., Gano, A., Badamgarav, E., Buist, A.S. & Mannino, D.M. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 28, 523-532 (2006). (Pubitemid 44794666)
49. Das, S., Mukherjee, S., Kundu, S., Mukherjee, D., Ghoshal, A.G. & Paul, D. Presence and severity of COPD among patients attending cardiology OPD of a tertiary healthcare centre. J. Indian Med. Assoc. 108, 406-409 (2010).
50. Gullón J.A, Suárez I., Medina A., Rubinos G., Fernández R., González I. Role of emphysema and airway obstruction in prognosis of lung cancer. Lung Cancer 71, 182-185 (2011).
51. Ishii, T., Wakabayashi, R., Kurosaki, H., Gemma, A. & Kida, K. Association of serotonin transporter gene variation with smoking, chronic obstructive pulmonary disease, and its depressive symptoms. J. Hum. Genet. 56, 41-46 (2011).
52. Vaquero-Barrios, J.M. et al. Bone mineral density in patients with chronic obstructive pulmonary disease who are candidates for lung transplant. Transplant. Proc. 42, 3020-3022 (2010).
53. Shapiro, S., Snider, G. & Rennard S. Chronic Bronchitis and Emphysema. Textbook of Respiratory Medicine. 4th ed. Elsevier: Philidelphia, PA, 2005. p. 1115.
54. Vestbo, J., Soørensen, T., Lange, P., Brix, A., Torre, P. & Viskum, K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353, 1819-1823 (1999). (Pubitemid 29251012)
55. Y ang, I.A., Fong, K.M., Sim, E.H., Black, P.N. & Lasserson, T.J. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. CD002991 (2007).
56. Halpin, D.M., Gray, J., Edwards, S.J., Morais, J. & Singh, D. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int. J. Clin. Pract. 65, 764-774 (2011).
57. Calverley, P. et al.; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361, 449-456 (2003). (Pubitemid 36173708)
58. Szafranski, W. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 21, 74-81 (2003). (Pubitemid 36150304)
59. Kohyama, T. et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am. J. Respir. Cell Mol. Biol. 26, 694-701 (2002). (Pubitemid 34557370)
60. Barnette, M.S. et al. SB 207499 (Ariflo), a potent and selective secondgeneration phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. 284, 420-426 (1998). (Pubitemid 28109574)
61. Profita, M. et al. Effect of cilomilast (Ariflo) on TNF-α, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 58, 573-579 (2003). (Pubitemid 36808126)
62. Kohyama, T. et al. Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblastmediated collagen gel degradation induced by tumor necrosis factor-α and neutrophil elastase. Am. J. Respir. Cell Mol. Biol. 27, 487-494 (2002).
63. Compton, C.H. et al.; International Study Group. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358, 265-270 (2001). (Pubitemid 32738964)
64. Gamble, E. et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 168, 976-982 (2003). (Pubitemid 37267176)
65. Rennard, S. et al. The efficacy and safety of cilomilast in COPD. Drugs 68 (suppl. 2), 3-57 (2008).
66. Rennard, S.I., Schachter, N., Strek, M., Rickard, K. & Amit, O. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 129, 56-66 (2006). (Pubitemid 43265243)
67. Hatzelmann, A. et al. The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 23, 235-256 (2010).
68. Hatzelmann, A. & Schudt, C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297, 267-279 (2001). (Pubitemid 32242587)
69. Kwak, H.J., Song, J.S., Heo, J.Y., Yang, S.D., Nam, J.Y. & Cheon, H.G. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J. Pharmacol. Exp. Ther. 315, 1188-1195 (2005).
70. Burgess, J.K. et al. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. J. Allergy Clin. Immunol. 118, 649-657 (2006). (Pubitemid 44301397)
71. Martorana, P.A., Beume, R., Lucattelli, M., Wollin, L. & Lungarella, G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am. J. Respir. Crit. Care Med. 172, 848-853 (2005). (Pubitemid 41369068)
72. Rabe, K.F., Bateman, E.D., O'Donnell, D., Witte, S., Bredenbröker, D. & Bethke, T.D. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366, 563-571 (2005). (Pubitemid 41140331)
73. Rennard, S.I., Calverley, P.M., Goehring, U.M., Bredenbröker, D. & Martinez, F.J. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir. Res. 12, 18 (2011).
74. Calverley, P.M., Rabe, K.F., Goehring, U.M., Kristiansen, S., Fabbri, L.M. & Martinez, F.J.; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374, 685-694 (2009).
75. Nycomed GmbH. Highlights of Prescribing Information: Daliresp (roflumilast) Tablets. Drug monograph, 2011.
76. Fabbri, L.M. et al.; M2-127 and M2-128 study groups. Roflumilast in moderateto-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374, 695-703 (2009).
77. Nials, A.T., Tralau-Stewart, C.J., Gascoigne, M.H., Ball, D.I., Ranshaw, L.E. & Knowles, R.G. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J. Pharmacol. Exp. Ther. 337, 137-144 (2011).
78. Vestbo, J., Tan, L., Atkinson, G. & Ward, J.; UK-500,001 Global Study Team. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur. Respir. J. 33, 1039-1044 (2009).